Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Amoxycillin (400mg) + Clavulanic Acid (57mg) Tablet
Therapeutic Category
Antibacterials, Antibiotic
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Moxyplit CV 457 Tablet (Amoxycillin 400 mg + Clavulanic acid 57 mg DT) is a highly effective, beta-lactamase inhibitor-protected antibiotic. The combination ensures Amoxycillin remains active against bacteria that have developed resistance. The Dispersible Tablet (DT) form is crucial for high patient compliance, especially in pediatric and geriatric care, making it a market powerhouse.
Key Commercial Value & Clinical Edge:
Resistance Coverage Clavulanic acid provides a crucial clinical edge against resistant bacterial strains, guaranteeing prescription by specialists when first-line antibiotics fail.
Dispersible Technology (DT) The DT formulation offers superior patient convenience (no swallowing issues) and faster absorption, securing its premium positioning in the pediatric and high-compliance segments.
Broad Spectrum Use This combination is the gold standard for treating severe respiratory tract infections (RTIs), complicated ear, nose, throat (ENT) infections, and skin/soft tissue infections.
Specialist Demand The product is heavily prescribed by Pediatricians, General Physicians, and Pulmonologists, ensuring robust, high-volume sales across primary and secondary healthcare markets.
Secure your exclusive Moxyplit CV 457 territory and capitalize on the premium, resistance-fighting antibiotic market!
Common side effects may include nausea, vomiting, diarrhea, abdominal discomfort, or mild rash. Rarely, allergic reactions such as hives, swelling, or difficulty breathing may occur. Persistent or severe symptoms should prompt immediate medical consultation.
Moxyplit CV 457 Tablet is indicated for the treatment of bacterial infections, including respiratory tract infections (sinusitis, bronchitis, pneumonia), urinary tract infections, skin and soft tissue infections, otitis media, and dental infections. It is especially useful for infections caused by beta-lactamase-producing bacteria that are resistant to amoxicillin alone.
Take Moxyplit CV 457 Tablet exactly as prescribed by your healthcare provider. Disperse the tablet in a small amount of water before administration if required. Complete the full course of therapy even if symptoms improve early to prevent bacterial resistance. Patients allergic to penicillin or with a history of liver or kidney disorders should use this medication under strict medical supervision.
Store Moxyplit CV 457 Tablet in a cool, dry place below 25°C, protected from moisture and sunlight. Keep out of reach of children and discard any unused portion after the expiry date.
Composition : Tolperisone (150mg) + Paracetamol (325mg)
Composition : Thiocolchicoside (4mg) + Aceclofenac (100mg) + Paracetamol (325mg) Tablet
Composition : Tolperisone (150mg) + Diclofenac (50mg)
Composition : Tolperisone (450mg) + Diclofenac (100mg)
Composition : Trypsin I.P. 48mg + Bromelain B.P. 90mg + Rutoside Trihydrate B.P. 100mg + Diclofenac I.P. 50mg
Composition : Tamsulosin (0.4mg) + Dutasteride (0.5mg)
Composition : Silodosin (8mg) + Dutasteride (0.5mg)
Composition : Timolol (5mg) + Brimonidine (2mg) Eye Drop
Composition : Tobramycin (0.3% w/v) + Fluorometholone (0.1% w/v)
Composition : Tranexamic Acid (500mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This pediatric-friendly antibiotic dispersible tablet has strong demand in the anti-infective and child healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on pediatric and general medicine portfolios.
Medical distributors and agencies can benefit from consistent demand for treatment of respiratory tract infections, throat infections, ear infections, sinus infections, urinary tract infections, and other bacterial infections in children. Amoxycillin helps eliminate infection-causing bacteria, while Clavulanic Acid enhances antibiotic effectiveness by overcoming bacterial resistance, strengthening a reliable pediatric antibiotic product portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this pediatric antibiotic dispersible tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong pediatric prescription demand, fast-moving anti-infective category, seasonal infection sales growth, reliable supply chain support, and good margins when partnering for this pediatric antibiotic product.
Medical distributors, stockists, and wholesalers interested in this pediatric antibiotic dispersible tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.